Kinase inhibitors
The disclosed molecules are inhibitors of Bcr-Abl and Src kinases. The molecules are cytotoxic to Gleevec resistant cells. Inhibitors of Bcr-Abl and Src kinases are used in the treatment of Chronic Myelogenous Leukemia among other diseases.
1. A formulation having kinase inhibitor activity, the formulation comprising:
a first component selected from the group consisting of compounds having a formula in accordance with the following:
wherein R 1 is selected from the group consisting of:
a) an aromatic ring substituted with a group selected from groups consisting of alkyl, alkoxy, —COOX 4 wherein X 4 is selected from H and an alkyl group with one to ten carbon atoms, nitrile groups, and halides, excluding said aromatic ring being solely substituted with a O—CH 3 group at the para position relative to the bond between the aromatic ring and the nitrogen,
b) a heterocyclic ring substituted with a group selected from groups consisting of alkyl, alkoxy, —COOX 4 wherein X 4 is selected from H and an alkyl group with one to ten carbon atoms, nitrile groups, and halides, and
c) a first ring selected from an aromatic ring and a heterocyclic ring, said first ring being linked to a second ring selected from an aromatic ring and a heteroaromatic ring, said first ring being substituted with a group selected from groups consisting of alkyl, alkoxy, —COOX 4 wherein X 4 is selected from H and an alkyl group with one to ten carbon atoms, nitrile groups, and halides,
wherein R 2 is selected from H and OX 5 where X 5 is selected from an alkyl group with one to ten carbon atoms, the radical —CH 2 —, and the radical —CH 2 CH 2 —,
wherein R 3 is selected from H and OX 6 where X 6 is selected from an alkyl group with one to ten carbon atoms, the radical —CH 2 —, and the radical —CH 2 CH 2 —,
wherein X 1 is selected from —CH—, —C(═O)—, and N,
wherein X 3 is selected from —CH—, —C(═O)—, and N,
wherein X 2 is selected from N, —O(X 7 )— where X 7 is selected from H, an alkyl group with one to ten carbon atoms, an alkoxy group, a nitrile, and a halide,
pharmaceutically acceptable derivatives of said compounds, and mixtures thereof; and
a pharmaceutically acceptable delivery vehicle.
2. The formulation according to claim 1 , wherein said first ring is directly linked to said second ring.
3. The formulation according to claim 1 , wherein said first ring is linked to said second ring through an amide bond.
4. The formulation according to claim 1 , wherein said second ring is substituted with a group selected from groups consisting of alkyl, alkoxy, —COOX 4 wherein X 4 is selected from H and an alkyl group with one to ten carbon atoms, nitrile groups, and halides.
5. The formulation according to claim 1 , wherein at least one of said first ring and said second ring has a basic group attached to improve solubility.
6. The formulation according to claim 1 , wherein X 5 is selected from the radicals —CH 2 — and —CH 2 CH 2 —, wherein X 6 is selected from the radicals —CH 2 — and —CH 2 CH 2 —, and X 5 and X 6 are linked together to form a heterocycle.
7. A formulation according to claim 1 , wherein said first component is selected from the group consisting of compounds having a formula as follows:
wherein R1 is selected from the group consisting of H, O—CH 3 , and COO—CH 3 , wherein R2 is selected from the group consisting of O—CH 3 , CH 3 , F, and H, wherein R3 is selected from the group consisting of CH 2 —CH 3 , CH 3 , and C E N, except that R1 may not be O—CH 3 when R2 is H,
derivatives of said compounds, and mixtures thereof.
8. The formulation according to claim 7 , wherein said derivatives of said compounds are selected from the group consisting of PEGylation products of said compounds, encapsulated forms of said compounds, encapsulated forms of said PEGylation products, complexes of said compounds, encapsulated forms of said complexes, conjugates of said compounds, encapsulated forms of said conjugates, prodrugs of said compounds, encapsulated forms of said prodrugs, and combinations thereof.
9. The formulation according to claim 8 , wherein said complexes or conjugates of said compounds are selected from protein-DNA complexes of said compounds, protein conjugates of said compounds, and mixtures thereof.
10. A method of inhibiting kinase activity in inflammatory cells, the method comprising the steps of:
providing a kinase inhibitor formulation according to claim 1 ; and
introducing the kinase inhibitor formulation to one or more inflammatory cells to thereby inhibit one or more kinases involved in one or more cell signaling pathways involved in progression of an inflammatory disease.
11. The formulation according to claim 8 , wherein each of said encapsulated forms of said compounds, said encapsulated forms of said PEGylation products, said encapsulated forms of said complexes, and said encapsulated forms of said conjugates is formed using any encapsulation means selected from the group consisting of encapsulation by micelles, encapsulation by liposomes, encapsulation by microspheres made of biodegradable polymer, encapsulation by albumin microspheres, encapsulation by synthetic polymers, encapsulation by nanofibers, encapsulation by multifunctional inorganic nanoparticles, encapsulation by erythrocytes, encapsulation by virosomes, encapsulation by dendrimers, and combinations thereof.
12. The formulation in accordance with claim 1 , wherein said first component is at least in part encapsulated using a pharmaceutically acceptable encapsulation means selected from the group consisting of micelles, liposomes, microspheres made of biodegradable polymer, albumin microspheres, synthetic polymer encapsulants, nanofibers, multifunctional inorganic nanoparticles, erythrocytes, virosomes, dendrimers, and combinations thereof.
13. The formulation according to claim 7 , wherein R1 is H, R2 is CH 3 , and R3 is CH 2 —CH 3 .
14. A method of inhibiting kinase activity in cancer cells, the method comprising the steps of:
providing a kinase inhibitor formulation according to claim 1 ; and
introducing the kinase inhibitor formulation to one or more cancer cells to thereby inhibit one or more kinases involved in one or more cell signaling pathways involved in progression of cancer.
15. A method of inhibiting kinase activity in cancer cells, the method comprising the steps of:
providing a kinase inhibitor formulation according to claim 7 ; and
introducing the kinase inhibitor formulation to one or more cancer cells to thereby inhibit one or more kinases involved in one or more cell signaling pathways involved in progression of cancer.
16. A method of inhibiting kinase activity in inflammatory cells, the method comprising the steps of:
providing a kinase inhibitor formulation according to claim 7 ; and
introducing the kinase inhibitor formulation to one or more inflammatory cells to thereby inhibit one or more kinases involved in one or more cell signaling pathways involved in progression of an inflammatory disease.
17. The formulation in accordance with claim 1 , wherein said pharmaceutically acceptable delivery vehicle is selected from the group consisting of cyclodextrins and mixtures thereof.